Skip to content
2000
  1. Home
  2. A-Z Publications
  3. MicroRNA
  4. Volume 14, Issue 1
  5. Article
Volume 14, Issue 1
  • ISSN: 2211-5366
  • E-ISSN: 2211-5374
file format pdf download PDF
file format text download EPUB
side by side viewer icon HTML

Abstract

Background

Myasthenia gravis is an autoimmune disease, and 30% of patients with thymoma often have myasthenia gravis. Patients with thymoma-associated MG (TAMG) have many different clinical presentations compared to non-MG thymoma (NMG), yet their gene expression differences remain unclear.

Objective

In this study, we analyzed the Differentially Expressed Genes (DEGs) and analyzed their regulatory microRNAs (miRNAs) in TAMG, which will further clarify the possible pathogenesis of TAMG.

Methods

DEGs were calculated using the RNA-sequencing data of TAMG and NMG downloaded from The Cancer Genome Atlas (TCGA) database. R software was then used to analyze the gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways of DEGs, while STRING was applied to build the protein-protein interaction (PPI) network and Cytoscape to identify and visualize the hub genes. Immune infiltration significances of hub genes were also explored by using the TIMER database and TCGA database. Upstream microRNAs (miRNAs) of the hub genes were predicted by online software.

Results

We comparatively analyzed the gene expression differences between TAMG and NMG groups. A total of 977 DEGs were identified between the two groups (|log fold change (FC)| >2, adjusted P value <0.050), with 555 down-regulated genes and 422 up-regulated genes. Five top hub genes (CTNNB1, EGFR, SOX2, ERBB2, and EGF) were recognized in the PPI network. Analysis based on the TIMER and TCGA databases suggested that 5 hub genes were correlated with multiple immune cell infiltrations and immune checkpoint-related markers, such as PDCD1, CTLA-4, and CD274, in TAMG patients. Lastly, 5 miRNAs were identified to have the potential function of regulating the hub gene expression.

Conclusion

Our study identified 5 hub genes (CTNNB1, EGFR, SOX2, ERBB2, and EGF) and their 5 regulatory miRNAs in TAMG, and the hub genes were correlated with multiple immune cell infiltrations and immune checkpoint-related markers. Our findings could help partially clarify the pathophysiology of TAMG, which could be new potential targets for subsequent clinical immunotherapy.

© 2025 Bentham Science Publishers
© 2025 The Author(s). Published by Bentham Science Publishers. This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/mirna/10.2174/0122115366299210240823062457
2024-08-26
2025-04-16

  • From This Site

    /content/journals/mirna/10.2174/0122115366299210240823062457
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
The full text of this item is not currently available.

References

  1. EngelsE.A. Epidemiology of thymoma and associated malignancies.J. Thorac. Oncol.2010510S260S26510.1097/JTO.0b013e3181f1f62d 20859116
     [Google Scholar]
  2. TartaroneA. LeroseR. LettiniA.R. TartaroneM. Current treatment approaches for thymic epithelial tumors.Life (Basel)2023135117010.3390/life13051170 37240815
     [Google Scholar]
  3. WillnerJ. ZhouF. MoreiraA.L. Diagnostic challenges in the cytology of thymic epithelial neoplasms.Cancers (Basel)2022148201310.3390/cancers14082013 35454918
     [Google Scholar]
  4. NakajimaJ. MurakawaT. FukamiT. SanoA. TakamotoS. OhtsuH. Postthymectomy myasthenia gravis: relationship with thymoma and antiacetylcholine receptor antibody.Ann. Thorac. Surg.200886394194510.1016/j.athoracsur.2008.04.070 18721587
     [Google Scholar]
  5. ThomasC.R. WrightC.D. LoehrerP.J. Thymoma: State of the Art.J. Clin. Oncol.19991772280228910.1200/JCO.1999.17.7.2280 10561285
     [Google Scholar]
  6. OkumuraM. FujiiY. ShionoH. Immunological function of thymoma and pathogenesis of paraneoplastic myasthenia gravis.Gen. Thorac. Cardiovasc. Surg.200856414315010.1007/s11748‑007‑0185‑8 18401674
     [Google Scholar]
  7. A neurologist’s perspective on understanding myasthenia gravis: clinical perspectives of etiologic factors, diagnosis, and preoperative treatment.Thorac. Surg. Clin.2019292133141
     [Google Scholar]
  8. GirardN. Ponce AixS. CedresS. Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial.ESMO Open20238310157610.1016/j.esmoop.2023.101576 37285717
     [Google Scholar]
  9. DuX. CuiJ. YuX. YuL. Risk factor analysis of thymoma resection and its value in guiding clinical treatment.Cancer Med.20231212134081341410.1002/cam4.6043 37156630
     [Google Scholar]
  10. DresserL. WlodarskiR. RezaniaK. SolivenB. Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations.J. Clin. Med.202110112235225110.3390/jcm10112235 34064035
     [Google Scholar]
  11. LinK. XuD. WangX. ShiJ. GaoW. Development of a basement membrane gene signature and identification of the potential candidate therapeutic targets for pancreatic cancer.Gland Surg.202312226328110.21037/gs‑23‑24 36915817
     [Google Scholar]
  12. LoveM.I. HuberW. AndersS. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2.Genome Biol.2014151255057010.1186/s13059‑014‑0550‑8 25516281
     [Google Scholar]
  13. RobinsonM.D. McCarthyD.J. SmythG.K. A bioconductor package for differential expression analysis of digital gene expression data.Bioinformatics201026113914010.1093/bioinformatics/btp616 19910308
     [Google Scholar]
  14. YuG. WangL.G. HanY. HeQ.Y. An R package for comparing biological themes among gene clusters.OMICS201216528428710.1089/omi.2011.0118 22455463
     [Google Scholar]
  15. MeringC. HuynenM. JaeggiD. SchmidtS. BorkP. SnelB. STRING: a database of predicted functional associations between proteins.Nucleic Acids Res.200331125826110.1093/nar/gkg034 12519996
     [Google Scholar]
  16. SzklarczykD. GableA.L. LyonD. STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets.Nucleic Acids Res.201947160761310.1093/nar/gky1131 30476243
     [Google Scholar]
  17. ChinC.H. ChenS.H. WuH.H. HoC.W. KoM.T. LinC.Y. cytoHubba: identifying hub objects and sub-networks from complex interactome.BMC Syst. Biol.20148S4S1110.1186/1752‑0509‑8‑S4‑S11 25521941
     [Google Scholar]
  18. HänzelmannS. CasteloR. GuinneyJ. GSVA: gene set variation analysis for microarray and RNA-Seq data.BMC Bioinformatics201314172110.1186/1471‑2105‑14‑7 23323831
     [Google Scholar]
  19. WangX. LiX. JiangW. High expression of RTN4IP1 predicts adverse prognosis for patients with breast cancer.Transl. Cancer Res.202312485987210.21037/tcr‑22‑2350 37180657
     [Google Scholar]
  20. ZhouG. SoufanO. EwaldJ. HancockR.E.W. BasuN. XiaJ. NetworkAnalyst 3.0: a visual analytics platform for comprehensive gene expression profiling and meta-analysis.Nucleic Acids Res.201947123424110.1093/nar/gkz240 30931480
     [Google Scholar]
  21. KwanV. UndaB.K. SinghK.K. Wnt signaling networks in autism spectrum disorder and intellectual disability.J. Neurodev. Disord.2016814510.1186/s11689‑016‑9176‑3 27980692
     [Google Scholar]
  22. MiroševičŠ. KhandelwalS. SušjanP. Correlation between Phenotype and Genotype in CTNNB1 Syndrome: A Systematic Review of the Literature.Int. J. Mol. Sci.202223201256410.3390/ijms232012564 36293418
     [Google Scholar]
  23. XiaoX. MoH. TuK. CTNNB1 mutation suppresses infiltration of immune cells in hepatocellular carcinoma through miRNA-mediated regulation of chemokine expression.Int. Immunopharmacol.20208910704310.1016/j.intimp.2020.107043
     [Google Scholar]
  24. ChenL. ZhouQ. LiuJ. ZhangW. CTNNB1 alternation is a potential biomarker for immunotherapy prognosis in patients with hepatocellular carcinoma.Front. Immunol.20211275956510.3389/fimmu.2021.759565 34777372
     [Google Scholar]
  25. OlayioyeM.A. NeveR.M. LaneH.A. HynesN.E. New embo members’ review: The ErbB signaling network: receptor heterodimerization in development and cancer.EMBO J.200019133159316710.1093/emboj/19.13.3159 10880430
     [Google Scholar]
  26. UckunF.M. QaziS. Upregulated expression of erbb2/her2 in multiple myeloma as a predictor of poor survival outcomes.Int. J. Mol. Sci.202324129943995810.3390/ijms24129943 37373090
     [Google Scholar]
  27. ZhangH. BerezovA. WangQ. ErbB receptors: from oncogenes to targeted cancer therapies.J. Clin. Invest.200711782051205810.1172/JCI32278 17671639
     [Google Scholar]
  28. PengS. WangR. ZhangX. EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression.Mol. Cancer201918116510.1186/s12943‑019‑1073‑4 31747941
     [Google Scholar]
  29. WangD. HaoS. HeH. Contribution of PGAP3 co‐amplified and co‐overexpressed with ERBB2 at 17q12 involved poor prognosis in gastric cancer.J. Cell. Mol. Med.202327162424243610.1111/jcmm.17828 37386793
     [Google Scholar]
  30. SarkarA. HochedlingerK. The sox family of transcription factors: versatile regulators of stem and progenitor cell fate.Cell Stem Cell2013121153010.1016/j.stem.2012.12.007 23290134
     [Google Scholar]
  31. TanJ.P. LiuX. PoloJ.M. Establishment of human induced trophoblast stem cells via reprogramming of fibroblasts.Nat. Protoc.202217122739275910.1038/s41596‑022‑00742‑2 36241724
     [Google Scholar]
  32. WeinaK. UtikalJ. SOX2 and cancer: current research and its implications in the clinic.Clin. Transl. Med.2014311910.1186/2001‑1326‑3‑19 25114775
     [Google Scholar]
  33. MaddisonP. GozzardP. SadalageG. Neuronal antibody detection and improved lung cancer prediction in Lambert-Eaton myasthenic syndrome.J. Neuroimmunol.202034057714910.1016/j.jneuroim.2020.577149 31951874
     [Google Scholar]
  34. XieY. LiH. JiangB. LiY. KaminskiH.J. KusnerL.L. Elevated plasma interleukin-17A in a subgroup of Myasthenia Gravis patients.Cytokine201678444610.1016/j.cyto.2015.06.011 26618234
     [Google Scholar]
  35. WangZ. WangW. ChenY. WeiD. T helper type 17 cells expand in patients with myasthenia-associated thymoma.Scand. J. Immunol.2012761546110.1111/j.1365‑3083.2012.02703.x 22486891
     [Google Scholar]
  36. LiuR.T. LiW. GuoD. Natural killer cells promote the differentiation of follicular helper T cells instead of inducing apoptosis in myasthenia gravis.Int. Immunopharmacol.20219810788010.1016/j.intimp.2021.107880 34174703
     [Google Scholar]
  37. GeM.R. YangC.L. LiT. Circulating CXCR5+ natural killer cells are expanded in patients with myasthenia gravis.Clin. Transl. Immunology2023125145010.1002/cti2.1450 37223338
     [Google Scholar]
  38. NiW.J. LengX.M. miRNA-Dependent Activation of mRNA Translation.MicroRNA201652838610.2174/2211536605666160825151201 27568791
     [Google Scholar]
  39. SunT. LiuZ. MicroRNA-139-5p suppresses non-small cell lung cancer progression by targeting ATAD2.Pathol. Res. Pract.202324915471910.1016/j.prp.2023.154719 37595446
     [Google Scholar]
/content/journals/mirna/10.2174/0122115366299210240823062457
Loading
Identification of Hub Genes and Analysis of their Regulatory miRNAs in Patients with Thymoma Associated Myasthenia Gravis Based on TCGA Database
MicroRNA 14, 49 (2025); https://doi.org/10.2174/0122115366299210240823062457
/content/journals/mirna/10.2174/0122115366299210240823062457
/content/journals/mirna/10.2174/0122115366299210240823062457
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher's website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): immune cell infiltration; KEGG; KWs; microrna; Myasthenia gravis; thymoma
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test